Table 1 Patient characteristics

From: Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

Characteristic n (out of 178) Percentage
Gender
Male 76 42.7%
Female 102 57.3%
Age (years)
Median (Q1–Q3) 61.0 (52.0–71.0)
Mean (s.d.) 60.6 (14.8)
≥70 years old 50 28.1%
Smoking
Never 89 50.6%
Former 43 24.4%
Current 20 11.4%
Unknown 24 13.6%
Comorbidities
Hypertension 65 36.5%
Diabetes 35 19.7%
Dyslipidemia 16 9.0%
Cardiac disease (ischemic/other) 9/21 5.1%/11.8%
Chronic kidney disease 10 5.6%
Autoimmune disease 9 5.1%
BMI
Median (Q1–Q3) 25.0 (22.0–28.0)
Mean (s.d.) 25.0 (4.9)
<18.5 12 7.4%
18.5–25 64 39.3%
25–30 62 38.0%
≥30 25 15.3%
History of cancer
Solid tumors 156a  
 Breast 32 20.5%
 Gynecological 23 14.7%
 Head and neck 22 14.1%
 Gastrointestinal 21 13.5%
 Genitourinary 20 12.8%
 Thoracic 17 10.9%
 Dermatology 11 7.1%
 Others (endocrine, CNS, ACUP) 10 6.4%
Hematological malignancies 30a  
 Mature B cell neoplasm/myeloma 15 50.0%
 Acute myeloid leukemia 8 26.7%
 Hodgkin lymphoma 4 13.3%
 Others 3 10.0%
Disease status
Remission/curative intent 70 39.3%
Active/advanced disease 108 60.7%
PS at last oncological visit
0/1 129 72.9%
≥2 48 27.1%
Systemic treatments in the past 3months
Yes 117 66.9%
Cytotoxic chemotherapy 66 37.1%
Target therapy 30 16.9%
Hormone therapy 16 10.3%
Immune checkpoint inhibitor 19 10.7%
  1. aTwo patients with a solid tumor had a history of hematological malignancy and six patients with a hematological malignancy had a history of solid tumor.
  2. ACUP, adenocarcinoma of unknown primary; CNS, central nervous system; PS, performance status; Q1, first quartile; Q3, third quartile.